Results 61 to 70 of about 2,265 (188)

Cost-effectiveness of tezepelumab in Canada for severe asthma

Journal of Medical Economics, 2023
To assess the cost-effectiveness of tezepelumab as add-on maintenance therapy compared with standard of care (SoC) for the treatment of patients with severe asthma in Canada. A cost utility analysis was conducted using a Markov cohort model with five health states (“controlled asthma”, “uncontrolled asthma”, “previously controlled asthma with ...
Mara Habash, Hannah Guiang, Irvin Mayers, Anna Quinton, Vivian Vuong, Aidan Dineen, Sumeet Singh, Danny Gibson, Adrian P. Turner   +8 more
openaire   +2 more sources

Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Post hoc analyses of clinical trials have characterized dupilumab's adverse effects, yet the real‐world impact in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma is not well described. This study aims to characterize the risks of lymphoma, cardiovascular events, eosinophilia, joint pain, inflammatory arthritis, and ...
Emma J. Anisman, Spencer Short, Emma Tam, Benjamin F. Bitner, Abdulghafoor Alani, Marc Rosen, Mindy Rabinowitz, Damaris Pena Evertz, Elina Toskala, Gurston G. Nyquist   +9 more
wiley   +1 more source

Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction

ERJ Open Research
Background Persistent airflow obstruction (PAO) in patients with asthma can be difficult to treat. Tezepelumab blocks thymic stromal lymphopoietin, an epithelial cytokine implicated in asthma pathogenesis.
Elliot Israel, Mario Castro, Christopher S. Ambrose, Jean-Pierre Llanos, Nestor A. Molfino, Nicole L. Martin, Sandhia S. Ponnarambil, Neil Martin   +7 more
doaj   +1 more source

Tackling "people remodelling" in corticosteroid-dependent asthma with type-2 targeting biologics and a formal corticosteroid weaning protocol [PDF]

, 2022
: People with severe corticosteroid-dependent asthma have greater morbidity, mortality and corticosteroid side effects than any other people with asthma. Just as type-2 inflammation and recurrent asthma attacks remodel airways, we propose the concept of ‘
Couillard, Simon, Lachapelle, Philippe, St-Germain, Olivier   +2 more
core   +2 more sources

Dysregulated proteolytic cascades in Netherton syndrome: from molecular pathology to preclinical drug testing

The Journal of Pathology, EarlyView.
Abstract Netherton syndrome (NS) is a rare, severe, and often life‐threatening disease for which current therapeutic approaches are limited and show variable effectiveness. NS is characterized by excessive epidermal desquamation that results in a highly defective epidermal barrier, constitutive skin inflammation, allergies, and hair abnormalities.
Eleni Zingkou, Evangelos Bisyris, Georgios Pampalakis, Georgia Sotiropoulou   +3 more
wiley   +1 more source

Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis

Journal of Asthma and Allergy, 2022
Zaid Zoumot,1 Nasser Al Busaidi,2 Wail Tashkandi,3 Ahmed A Aljohaney,4 Said Isse,1 Kota Vidyasagar,5 Kingsley Nnanna Ukwaja6 1Respiratory Institute Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; 2Department of Pulmonology, Royal Hospital ...
Zoumot Z, Al Busaidi N, Tashkandi W, Aljohaney AA, Isse S, Vidyasagar K, Ukwaja KN   +6 more
doaj  

Precision Medicine in Targeted Therapies for Severe Asthma:Is There Any Place for "omics" Technology? [PDF]

, 2018
According to the current guidelines, severe asthma still represents a controversial topic in terms of definition and management. The introduction of novel biological therapies as a treatment option for severe asthmatic patients paved the way to a ...
Bertolini, Francesca, Caminati, Marco, Facciolongo, Nicola, Galeone, Carla, Menzella, Francesco, Ruggiero, Patrizia, Scelfo, Chiara   +6 more
core   +2 more sources

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Allergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui   +7 more
wiley   +1 more source

Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications—An EAACI Task Force Report

Allergy, EarlyView.
ABSTRACT Chronic rhinosinusitis (CRS) and asthma are prevalent conditions that often coexist. These diseases share common inflammatory mechanisms, such as T‐helper cell 2 (T2)‐high inflammation, driven by interleukin (IL)‐4, IL‐5, and IL‐13 cytokines.
Sanna Toppila‐Salmi, Sietze Reitsma, Valérie Hox, Simon Gane, Philippe Gevaert, Juan Maza‐Solano, Alma Helevä, Ida Sulku, Kaisa Santala, Iiris Kangasniemi, Ludger Klimek, Adam Chaker, Aspasia Karavelia, Michael Rudenko, Oliver Pfaar, Laura Van Gerven, Shaari Ariana, Michele Schiappoli, Marie Lundberg, Jan Hagemann, Ibon Eguíluz‐Gracia, Andre Moreira   +21 more
wiley   +1 more source

Tezepelumab for severe asthma: elevating current practice to recognize epithelial driven profiles

Respiratory Research
Background An increasing amount of evidence supports the relevance of epithelium across the wide spectrum of asthma pathobiology. On a clinical ground tezepelumab, selectively binding TSLP, a major epithelial cytokine, has demonstrated to be effective in
Marco Caminati, A. Vatrella, P. Rogliani, E. Carpagnano, A. Spanevello, G. Senna   +5 more
doaj   +1 more source